首页> 美国卫生研究院文献>Oncotarget >Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai China
【2h】

Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai China

机译:CD64表达模式和密度的流式细胞术分析在急性早幼粒细胞白血病中的诊断:在中国上海的一项多中心研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

No unified immunophenotypic profiles and corresponding analytic strategies have been established for the rapid diagnosis of acute promyelocytic leukemia (APL) using flow cytometry (FCM). Here we describe a characteristic immunophenotypic panel that can rapidly and accurately distinguish APL from other types of adult acute myeloid leukemia (AML) using only FCM. By comparing APL cells and non-APL AML cells that share APL common immunophenotypes (CD34CD117+HLADR) we found that CD64 was a significant factor that differentiated APL from other AMLs. Further retrospective analyses of 205 APL and 629 non-APL AML patients from different hematology centers showed that either the CD64dim and homoCD13+homo CD33+homoMPO+ (myeloperoxidase) CD11c panel or the CD64dim and homoCD13+homo CD33+homoMPO+ CD11c+CD10CD117+ SSChigh (high side scatter signal) panel could distinguish APL from non-APL AML patients with nearly 100% sensitivity, specificity and accuracy. Moreover, relative quantification of CD64 expression enhanced the applicability of our APL diagnostic immunophenotypic panels (ADI-panels) in different hematology centers. Application of the ADI-panels will decrease diagnosis time and improve personalized treatment for APL, a life-threatening disease with very rapid progression.
机译:还没有使用流式细胞仪(FCM)快速诊断急性早幼粒细胞白血病(APL)的统一免疫表型概况和相应的分析策略。在这里,我们描述了一个特征性的免疫表型面板,可以仅使用FCM就能快速,准确地将APL与其他类型的成人急性髓细胞性白血病(AML)区别开来。通过比较共享APL常见免疫表型(CD34 - CD117 + HLA - DR -的APL细胞和非APL AML细胞sup>),我们发现CD64是将APL与其他AML区别开的重要因素。对来自不同血液学中心的205名APL和629名非APL AML患者进行的进一步回顾性分析表明,CD64 dim和homo CD13 + homo CD33 + homo MPO + (髓过氧化物酶)CD11c -面板或CD64 dim和hom CD13 + homo CD33 + homo MPO + CD11c + CD10 - CD117 + SSC (高侧向散射信号)面板可以将APL与非APL AML患者区分开,灵敏度,特异性和准确性均接近100%。此外,CD64表达的相对定量增强了我们APL诊断免疫表型板(ADI-panels)在不同血液学中心的适用性。 ADI面板的应用将减少诊断时间并改善针对APL的个性化治疗,APL是一种威胁生命的疾病,进展很快。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号